‎MARAFIQ goes ex-dividend, GO ex-rights today

MARAFIQ goes ex-dividend, Etihad Atheeb ex-rights today

Tadawul trading screen


Shares of Power and Utility Company for Jubail and Yanbu’s (MARAFIQ) have their ex-dividend today, March 8, for H2 2022.

In addition, shares of Etihad Atheeb Telecommunication Co. (GO) have their ex-rights today, in case the capital increase is approved.

Company Going Ex-dividend, Rights Today

Company

Distribution rate (%)

Distribution date

Details

MARAFIQ

11% cash dividend for H2 2022

March 23

For more details

GO

2.78 rights for every share held

For more details

For More IPOs

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Repair or avalanche?  "I would be surprised if there are positive returns in the stock market in 2022" thumbnail

Repair or avalanche? “I would be surprised if there are positive returns in the stock market in 2022”

שוק ההון שנת 2022 נפתחה עם ירידות חדות בשווקים, והמשקיעים מודאגים ■ יונתן כץ מלידר: "כשמסתכלים על השנה כולה יש הרבה רוח לפנים" ■ אלכס זבז'ינסקי ממיטב: "השוק המשיך לעלות הרבה פעמים לאורך ההיסטוריה תוך כדי העלאות ריבית" הינך עוקב בהצלחה אחרי שלי אפלברג. ניתן לראות עדכונים על כתבות חדשות בעמוד הארץ שלי שלי אפלברג…
Read More
JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building thumbnail

JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building

SHANGHAI, Jan. 9, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, recently announced the appointments of Dr. Shaun Paul Cordoba as Chief Scientific Officer (CSO) and Raymond J. Hage, Jr. as Senior Vice President (SVP) of Corporate Development. In the newly created…
Read More
Traditional B2B Sales and Marketing Are Becoming Obsolete thumbnail

Traditional B2B Sales and Marketing Are Becoming Obsolete

Long the elusive objective of virtually every B2B commercial team, the time for sales and marketing “integration,” has passed. Instead, the most progressive B2B commercial organizations are completely reconfiguring commercial operations to better address today’s deep misalignment between how suppliers sell and how buyers buy. Most B2B sales and marketing teams typically function in a…
Read More
Expectations build for more than three US rate rises this year thumbnail

Expectations build for more than three US rate rises this year

Choose your subscription Trial Try full digital access and see why over 1 million readers subscribe to the FT For 4 weeks receive unlimited Premium digital access to the FT's trusted, award-winning business news Digital Be informed with the essentialnews and opinion MyFT – track the topics most important to you FT Weekend – full…
Read More
Index Of News
Total
0
Share